Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...
YolTech Therapeutics is set to commence a trial of its in vivo gene editing therapy, YOLT-204, aimed at treating TDT.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback